These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15741775)

  • 1. Formoterol delivered via a new multi-dose dry powder inhaler (Certihaler) is as effective and well tolerated as the formoterol dry powder inhaler (Aerolizer) in children with persistent asthma.
    Chuchalin AG; Manjra AI; Rozinova NN; Skopková O; Cioppa GD; Till D; Kaiser G; Fashola T; Kottakis J
    J Aerosol Med; 2005; 18(1):63-73. PubMed ID: 15741775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma.
    Dahl R; Creemers JP; Van Noord J; Sips A; Della Cioppa G; Thomson M; Andriano K; Kottakis J; Fashola T
    Respiration; 2004; 71(2):126-33. PubMed ID: 15031566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of formoterol delivered via a new multidose dry powder inhaler (Certihaler) in adolescents and adults with persistent asthma.
    LaForce C; Prenner BM; Andriano K; Lavecchia C; Yegen U
    J Asthma; 2005 Mar; 42(2):101-6. PubMed ID: 15871441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study.
    Busse W; Levine B; Andriano K; Lavecchia C; Yegen U
    Clin Ther; 2004 Oct; 26(10):1587-98. PubMed ID: 15598475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinically equivalent bronchodilatation achieved with formoterol delivered via Easyhaler and Aerolizer.
    Dubakiene R; Nargela R; Sakalauskas R; Vahteristo M; Silvasti M; Lähelmä S
    Respiration; 2006; 73(4):441-8. PubMed ID: 16432294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formoterol delivered via the dry powder Aerolizer inhaler versus albuterol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial.
    Pleskow W; LaForce CF; Yegen U; Matos D; Della Cioppa G
    J Asthma; 2003; 40(5):505-14. PubMed ID: 14529100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer.
    Lecaillon JB; Kaiser G; Palmisano M; Morgan J; Della Cioppa G
    Eur J Clin Pharmacol; 1999 Apr; 55(2):131-8. PubMed ID: 10335908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler.
    Bensch G; Lapidus RJ; Levine BE; Lumry W; Yegen U; Kiselev P; Della Cioppa G
    Ann Allergy Asthma Immunol; 2001 Jan; 86(1):19-27. PubMed ID: 11206232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler.
    Berger WE; Noonan MJ
    J Asthma; 2010 May; 47(4):447-59. PubMed ID: 20528601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma.
    Bensch G; Berger WE; Blokhin BM; Socolovsky AL; Thomson MH; Till MD; Castellsague J; Della Cioppa G;
    Ann Allergy Asthma Immunol; 2002 Aug; 89(2):180-90. PubMed ID: 12197575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
    Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G
    Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute relief of exercise-induced bronchoconstriction by inhaled formoterol in children with persistent asthma.
    Hermansen MN; Nielsen KG; Buchvald F; Jespersen JJ; Bengtsson T; Bisgaard H
    Chest; 2006 May; 129(5):1203-9. PubMed ID: 16685010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk).
    Benhamou D; Cuvelier A; Muir JF; Leclerc V; Le Gros V; Kottakis J; Bourdeix I
    Respir Med; 2001 Oct; 95(10):817-21. PubMed ID: 11601748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formoterol, 24 microg bid, and serious asthma exacerbations: similar rates compared with formoterol, 12 microg bid, with and without extra doses taken on demand, and placebo.
    Wolfe J; Laforce C; Friedman B; Sokol W; Till D; Della Cioppa G; van As A
    Chest; 2006 Jan; 129(1):27-38. PubMed ID: 16424410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study.
    Houghton CM; Langley SJ; Singh SD; Holden J; Monici Preti AP; Acerbi D; Poli G; Woodcock A
    Br J Clin Pharmacol; 2004 Oct; 58(4):359-66. PubMed ID: 15373928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bronchodilation and bronchoprotection in asthmatic preschool children from formoterol administered by mechanically actuated dry-powder inhaler and spacer.
    Nielsen KG; Bisgaard H
    Am J Respir Crit Care Med; 2001 Jul; 164(2):256-9. PubMed ID: 11463597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96 microg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients.
    Molimard M; Guenolé E; Duvauchelle T; Vicaut E; Lefrançois G
    Respiration; 2005; 72 Suppl 1():28-34. PubMed ID: 15915010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formoterol 12 microg BID administered via single-dose dry powder inhaler in adults with asthma suboptimally controlled with salmeterol or on-demand salbutamol: a multicenter, randomized, open-label, parallel-group study.
    Brambilla C; Le Gros V; Bourdeix I;
    Clin Ther; 2003 Jul; 25(7):2022-36. PubMed ID: 12946548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of formoterol delivered through the Novolizer, a novel dry powder inhaler (DPI) compared with a standard DPI in patients with moderate to severe asthma.
    Otto-Knapp R; Conrad F; Hösch S; Metzenauer P; Maus J; Noga O; Petzold U; Kunkel G
    Pulm Pharmacol Ther; 2008; 21(1):47-53. PubMed ID: 17475527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.